Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
20 earlier
The approval of Hibsago has created a new market for a handful of biopharmas, including Gilead, Arrowhead, and Vir, to fill in.
Original title: “GSK, Ionis hepatitis B functional cure breaks open market for followers”
Aside from RG6540, Roche also discontinued a host of other early-stage assets, including an antisense oligonucleotide for Alzheimer’s disease and a small-molecule candidate for geographic atrophy.
Original title: “Roche’s pipeline trim claims Poseida’s off-the-shelf CAR T asset”
In this episode of Denatured, you’ll hear from Bruce Culleton, CEO at ProKidney and Demetri Maxim, CEO at Nephrogen. We discuss why kidney disease has long been a hard target for cell and gene therapies, and what new delivery strategies, therapeutic approaches and regulatory clarity mean for commercially viable products.
Original title: “Why investors are taking another look at kidney disease”
At the European Society for Medical Oncology meeting this weekend, Merck will showcase three late-stage trials of its Kelun-Biotech–partnered TROP2-directed antibody sac-TMT that VP of Chemistry Alan Northrup says gets the payload release “just right.”
Original title: “ESMO 2026: Merck’s Kelun-partnered ADC hits the ‘Goldilocks zone,’ VP says”
Securing financing that allowed an exit from academia, leaving ecology and evolutionary biology for biomedical engineering and shifting from business development to entrepreneurship are among key turning points for three biopharma professionals.
Original title: “Critical decisions that spurred these 40 Under 40 winners to success”
New follow-up results suggest Arcus’ drug might be superior to a marketed Merck medicine. Elsewhere, Eli Lilly and AstraZeneca forged new partnerships.
Original title: “Arcus kidney cancer data impresses analysts; TriGemX inks a SPAC deal”
Looking for a remote biopharma position? Check out the BioSpace list of eight companies hiring life sciences professionals like you.
Original title: “8 companies hiring remote workers”
Mark Cuban's Cost Plus Drugs says it can reduce manufacturing costs for custom rare disease drugs and n-of-1 gene therapies. Mark Cuban's Cost Plus Drugs seeks to reduce manufacturing costs for custom rare disease drugs and n-of-1 gene therapies with new fill-finish plant in Dallas. “Saw your article on baby KJ and n of 1 therapies,” Mark Cuban wrote to a STAT reporter. Now he has news with Cost Plus Drugs.Jason Mendez/Getty Images for Samsung Electronics America ... Oct. 21, 2026 ... Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. One shipment contained DNA-like molecules crafted by California chemists to patch the rare genetic mutation destroying a single patient’s neurons. Another carried DNA-like molecules developed with Dutch researchers to stop a rare disease that causes adults to progressively lose control of their muscles. They are the first test of Cuban’s newest vision for his company Cost Plus Drugs: shake up the business of custom-made rare disease medicines.
Original title: “Mark Cuban's Cost Plus Drugs tackles expensive rare disease treatments | STAT”
A strong crossover raise can suggest that a company has “reached a level of maturity” and could go public soon, according to Sofinnova Investments’ Jim Healy.
Original title: “The 6 biggest crossover rounds in biopharma history”
Despite what some analysts described as low expectations, RAP-219 narrowly hit the main goal of a mid-stage study, results that could help it tap a billion-dollar-plus market opportunity.
Original title: “Rapport’s epilepsy drug finds surprising success in bipolar trial”
In this bonus episode, BioSpace Vice President of Marketing Chantal Dresner and Angela Gabriel, content manager, life sciences careers, discuss how the job market shaped up in Q3 and what Q4 might hold.
Original title: “Bonus: Q3 2026 Job Market Update”
METiS TechBio’s AiLNP platform uses machine learning models to develop lipid nanoparticles with potentially better tissue specificity that could enhance a drug’s therapeutic performance.
Original title: “Lilly puts $1.1B on the line for Hong Kong biotech’s AI drug delivery platform”
Posted on 20, October 2026 by ... safety monitoring and smarter clinical trials, hypertension care, M42, Middle East, Mike Sicilia, oncology, Oracle, Oracle Health and Life Sciences, Pascal Soriot, patient outcomes, rare disease, Real-World Data, real-world evidence, ... Posted on 20, October 2026 by EuropaWire PR Editors | This entry was posted in Healthcare, Pharma & Biotech, Technology, United Kingdom and tagged Abu Dhabi, AI in healthcare, Anne-Claire Gerbaldi, artificial-intelligence, AstraZeneca, AstraZeneca and Oracle launch global AI collaboration to support clinical research and care workflows, AstraZeneca and Oracle unveil international AI partnership for trial recruitment and patient care, AstraZeneca Oracle collaboration aims to connect scientific research with clinical workflows worldwide, AstraZeneca teams with Oracle and M42 on Abu Dhabi hyperte Initial areas of exploration include clinical trial recruitment, earlier diagnosis, drug-safety monitoring and the use of real-world evidence across the lifecycle of a medicine. Programmes will span AstraZeneca’s core disease areas, including oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology, and rare disease. Bringing together the unique capabilities of Oracle and AstraZeneca, we believe we can support smarter clinical trials, strengthen safety monitoring and help ensure patients are diagnosed sooner and receive the right care.” · Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences, said: “Healthcare progress depends on shortening the distance between scientific insight and the decisions clinicians make every day. AstraZeneca brings deep scientific and therapeutic expertise, and Oracle will deliver the secure data, cloud, AI, and clinical workflow capabilities. AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Disease, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Original title: “AstraZeneca and Oracle partner on AI-driven clinical trial optimisation and patient care | EuropaWire”
New types of bispecifics, antibody-drug conjugates and cell therapies haven’t yet proven themselves in the clinic. Pharmaceutical companies are betting billions anyway.
Original title: “Hype vs. reality: What pharma’s hottest R&D bets have actually proved”